SE0300033L - Användning av stammar av Parapoxviruset ovis mot organfibroser - Google Patents

Användning av stammar av Parapoxviruset ovis mot organfibroser

Info

Publication number
SE0300033L
SE0300033L SE0300033A SE0300033A SE0300033L SE 0300033 L SE0300033 L SE 0300033L SE 0300033 A SE0300033 A SE 0300033A SE 0300033 A SE0300033 A SE 0300033A SE 0300033 L SE0300033 L SE 0300033L
Authority
SE
Sweden
Prior art keywords
liver
parapoxvirus
strains
organ fibrosis
against organ
Prior art date
Application number
SE0300033A
Other languages
English (en)
Swedish (sv)
Other versions
SE0300033D0 (sv
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SE0300033D0 publication Critical patent/SE0300033D0/xx
Publication of SE0300033L publication Critical patent/SE0300033L/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/76Viruses; Subviral particles; Bacteriophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24211Parapoxvirus, e.g. Orf virus
    • C12N2710/24232Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE0300033A 2000-07-11 2003-01-10 Användning av stammar av Parapoxviruset ovis mot organfibroser SE0300033L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (2)

Publication Number Publication Date
SE0300033D0 SE0300033D0 (sv) 2003-01-10
SE0300033L true SE0300033L (sv) 2003-03-10

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0300033A SE0300033L (sv) 2000-07-11 2003-01-10 Användning av stammar av Parapoxviruset ovis mot organfibroser

Country Status (30)

Country Link
US (1) US6632647B2 (et)
EP (1) EP1303302B1 (et)
JP (1) JP5106736B2 (et)
CN (1) CN1452496B (et)
AR (1) AR028800A1 (et)
AU (2) AU8582701A (et)
BG (1) BG107447A (et)
CA (1) CA2415399C (et)
CZ (1) CZ200372A3 (et)
DK (1) DK200300014A (et)
EE (1) EE200300019A (et)
FI (1) FI20030038A (et)
GB (1) GB2383752B (et)
HK (1) HK1054330B (et)
HR (1) HRP20030097A2 (et)
HU (1) HU227668B1 (et)
IL (1) IL153826A0 (et)
LT (1) LT5064B (et)
LU (1) LU90996B1 (et)
LV (1) LV12991B (et)
MA (1) MA25765A1 (et)
MX (1) MXPA03000278A (et)
NO (1) NO20030081D0 (et)
NZ (1) NZ523535A (et)
PL (1) PL360839A1 (et)
RU (1) RU2003104522A (et)
SE (1) SE0300033L (et)
SI (1) SI21171A (et)
SK (1) SK382003A3 (et)
WO (1) WO2002004019A2 (et)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
AU2002353031A1 (en) 2001-12-07 2003-06-23 Bayer Corporation Use of parapox b2l protein to treat cancer and modify immune responses
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1574211A1 (en) * 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
EA201891848A1 (ru) * 2016-02-16 2019-02-28 Осака Юниверсити Фармацевтическая композиция для применения в лечении фиброза
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis;PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT885013E (pt) * 1996-04-15 2002-01-30 Anton Mayr Prof Dr Med Vet Dr Utilizacao de indutores de para-imunidade multipotentes baseados em poxvirus ou parapoxvirus atenuados e nao imunogenicos para a fabricacao de medicamentos
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
HU227668B1 (en) 2011-11-28
AR028800A1 (es) 2003-05-21
PL360839A1 (en) 2004-09-20
GB0302629D0 (en) 2003-03-12
RU2003104522A (ru) 2004-06-27
CA2415399A1 (en) 2003-01-08
HUP0303830A3 (en) 2004-10-28
NZ523535A (en) 2004-12-24
WO2002004019A3 (de) 2002-08-01
MA25765A1 (fr) 2003-04-01
NO20030081L (no) 2003-01-08
EE200300019A (et) 2004-10-15
CA2415399C (en) 2011-11-08
AU2001285827B2 (en) 2006-11-30
SE0300033D0 (sv) 2003-01-10
GB2383752B (en) 2004-11-24
LU90996B1 (en) 2003-01-08
US20020076418A1 (en) 2002-06-20
FI20030038A (fi) 2003-03-10
LT2003008A (en) 2003-07-25
HRP20030097A2 (en) 2005-02-28
CN1452496A (zh) 2003-10-29
JP2004502741A (ja) 2004-01-29
JP5106736B2 (ja) 2012-12-26
US6632647B2 (en) 2003-10-14
AU8582701A (en) 2002-01-21
EP1303302A2 (de) 2003-04-23
IL153826A0 (en) 2003-07-31
GB2383752A (en) 2003-07-09
MXPA03000278A (es) 2004-04-05
CN1452496B (zh) 2012-10-10
CZ200372A3 (cs) 2003-05-14
HK1054330B (zh) 2005-07-15
NO20030081D0 (no) 2003-01-08
BG107447A (bg) 2003-09-30
SI21171A (sl) 2003-10-31
SK382003A3 (en) 2003-07-01
HUP0303830A2 (hu) 2004-04-28
HK1054330A1 (en) 2003-11-28
DK200300014A (da) 2003-03-07
WO2002004019A2 (de) 2002-01-17
EP1303302B1 (de) 2009-10-14
LT5064B (lt) 2003-11-25
LV12991B (en) 2003-08-20

Similar Documents

Publication Publication Date Title
HK1122291A1 (en) Anti-viral compounds
EA200700243A1 (ru) Способы лечения гепатита с
HK1122292A1 (en) Anti-viral compounds
WO2007081517A8 (en) Anti-viral compounds
EA200300810A1 (ru) Вирус, вызывающий заболевание дыхательных путей у восприимчивых млекопитающих
WO2008133753A3 (en) Anti-viral compounds
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
EA200600582A1 (ru) Способы и композиции для лечения вирусного гепатита с
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
NO20085243L (no) Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
NO20075815L (no) Formuleringer og metoder for behandling av amyloidose
NO20052136L (no) Vaksine mot Hepatitt C-virus (HCV).
WO2010047830A3 (en) Agents for hcv treatment
WO2006093793A3 (en) Compositions comprising actinidia and methods of use thereof
BR0108499A (pt) Agente terapêutico para hepatite c
SE0300033L (sv) Användning av stammar av Parapoxviruset ovis mot organfibroser
DK1675603T3 (da) Anvendelse af probiotiske bakterier i behandling af infektion
SE0300034D0 (sv) Use of strains of the parapox ovis virus for producting antiviral pharmaceuticals and anticancer pharmaceuticals
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
MX2007002659A (es) Composicion vacunal contra el virus de la hepatitis c.
MXPA02011969A (es) Metodos para el tratamiento de padecimientos virales con il-18 y combinaciones de il-18.
EA200301151A1 (ru) Вакцина против натуральной оспы
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
WO2005094236A3 (en) Activation of hypoxia-inducible gene expression

Legal Events

Date Code Title Description
NAV Patent application has lapsed